SLGL - Sol-Gel's stock rises as FDA approves Epsolay to treat skin condition rosacea

The Food and Drug Administration (FDA) approved Sol-Gel Technologies (NASDAQ:SLGL) Epsolay, a proprietary cream formulation of benzoyl peroxide 5%, to treat inflammatory lesions of rosacea in adults. The company said the benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules, which is designed to slowly release benzoyl peroxide over time. The company said the approval was backed by data from two phase 3 trials which evaluated Epsolay against vehicle in people with inflammatory lesions of rosacea, a skin condition that causes red spots on the face. Israel-based Sol-Gel noted that it has granted Galderma Holding exclusive rights to commercialize Epsolay in the U.S. SLGL +6.39% to $7.83 premarket April 25

For further details see:

Sol-Gel's stock rises as FDA approves Epsolay to treat skin condition rosacea